277 related articles for article (PubMed ID: 22609059)
1. Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.
Jou YC; Tsai YS; Hsieh HY; Chen SY; Tsai HT; Chen KJ; Wang ST; Shiau AL; Wu CL; Tzai TS
Urol Oncol; 2013 Nov; 31(8):1806-11. PubMed ID: 22609059
[TBL] [Abstract][Full Text] [Related]
2. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of prothymosin-alpha expression in human upper urinary tract transitional cell carcinoma.
Jou YC; Tung CL; Tsai YS; Shen CH; Syue-Yi C; Shiau AL; Tsai HT; Wu CL; Tzai TS
Urology; 2009 Oct; 74(4):951-7. PubMed ID: 19679339
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic impact of p63 immunoreactivity in renal malignancies.
Tuna B; Unlu M; Aslan G; Secil M; Yorukoglu K
Anal Quant Cytol Histol; 2009 Apr; 31(2):118-22. PubMed ID: 19402389
[TBL] [Abstract][Full Text] [Related]
5. Serum Hepcidin and GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and renal cell carcinoma.
Traeger L; Ellermann I; Wiethoff H; Ihbe J; Gallitz I; Eveslage M; Moritz R; Herrmann E; Schrader AJ; Steinbicker AU
BMC Cancer; 2019 Jan; 19(1):74. PubMed ID: 30646851
[TBL] [Abstract][Full Text] [Related]
6. Serum level of ANGPTL4 as a potential biomarker in renal cell carcinoma.
Dong D; Jia L; Zhou Y; Ren L; Li J; Zhang J
Urol Oncol; 2017 May; 35(5):279-285. PubMed ID: 28110976
[TBL] [Abstract][Full Text] [Related]
7. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
[TBL] [Abstract][Full Text] [Related]
8. Renal collecting (Bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma.
Orsola A; Trias I; Raventós CX; Español I; Cecchini L; Orsola I
Urology; 2005 Jan; 65(1):49-54. PubMed ID: 15667862
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological characteristics and outcomes of synchronous renal cell carcinoma and urothelial carcinoma: A population-based analysis.
Wu K; Liu X; Wang Y; Wang X; Li X
Front Public Health; 2022; 10():994351. PubMed ID: 36388369
[TBL] [Abstract][Full Text] [Related]
10. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
Saito K; Kihara K
Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
[TBL] [Abstract][Full Text] [Related]
11. Lymphadenectomy for renal cell carcinoma and urothelial carcinoma of the upper urinary tract: analysis of evidence in the minimally invasive era.
Geller R; Hemal S; Manny T
Minerva Med; 2013 Jun; 104(3):261-72. PubMed ID: 23748280
[TBL] [Abstract][Full Text] [Related]
12. Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer.
Tzai TS; Tsai YS; Shiau AL; Wu CL; Shieh GS; Tsai HT
Urology; 2006 Feb; 67(2):294-9. PubMed ID: 16461079
[TBL] [Abstract][Full Text] [Related]
13. Circulating adiponectin as a biomarker in renal cell carcinoma: a systematic review and meta-analysis.
Yap NY; Yap FN; Perumal K; Rajandram R
Biomarkers; 2019 Sep; 24(6):607-614. PubMed ID: 31215811
[No Abstract] [Full Text] [Related]
14. Loss of nuclear prothymosin-α expression is associated with disease progression in human superficial bladder cancer.
Tsai YS; Jou YC; Tung CL; Lin CT; Shen CH; Chen SY; Tsai HT; Lai CL; Wu CL; Tzai TS
Virchows Arch; 2014 Jun; 464(6):717-24. PubMed ID: 24733561
[TBL] [Abstract][Full Text] [Related]
15. Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels.
Horstmann M; Merseburger AS; von der Heyde E; Serth J; Wegener G; Mengel M; Feil G; Hennenlotter J; Nagele U; Anastasiadis A; Bokemeyer C; Stenzl A; Kuczyk M
J Cancer Res Clin Oncol; 2005 Nov; 131(11):715-22. PubMed ID: 16080018
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Prognostic Effect of Plasma Fibrinogen in Renal Cell Carcinoma: A Meta-Analysis.
Tian Y; Hong M; Jing S; Liu X; Wang H; Wang X; Kaushik D; Rodriguez R; Wang Z
Biomed Res Int; 2017; 2017():9591506. PubMed ID: 28154828
[No Abstract] [Full Text] [Related]
17. Pyruvate kinase type tumor M2 in urological malignancies.
Hegele A; Varga Z; Kosche B; Stief T; Heidenreich A; Hofmann R
Urol Int; 2003; 70(1):55-8. PubMed ID: 12566817
[TBL] [Abstract][Full Text] [Related]
18. Expression of miR-100 as a novel ancillary non-invasive biomarker for early detection of bladder carcinoma.
Qureshi A; Fahim A; Kazi N; Farsi Kazi SA; Nadeem F
J Pak Med Assoc; 2018 May; 68(5):759-763. PubMed ID: 29885177
[TBL] [Abstract][Full Text] [Related]
19. [Utility of the serum CRP value for assessing the prognosis and therapeutic response of urological malignancies].
Köhler A; Eggers H; Kuczyk MA; Schrader AJ; Steffens S
Aktuelle Urol; 2013 Nov; 44(6):452-5. PubMed ID: 24258396
[TBL] [Abstract][Full Text] [Related]
20. Serum level of immunosuppressive acidic protein in patients with urological malignancies.
Pu YS; Tsai TC; Chiu TY; Hsieh TS; Chen J; Chen SC; Lin MC; Hsu TC
J Formos Med Assoc; 1991 May; 90(5):498-503. PubMed ID: 1680990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]